{"id":"early-dual-antiplatelet-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding/hemorrhage"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic approach typically combines aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide complementary antiplatelet effects. The dual mechanism targets multiple pathways of platelet activation, providing more potent inhibition of clot formation compared to monotherapy, particularly in acute cardiovascular events.","oneSentence":"Early dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:26.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke (early intervention)"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT07379190","phase":"PHASE3","title":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","status":"NOT_YET_RECRUITING","sponsor":"Weifang Medical University","startDate":"2026-02-01","conditions":"Stroke, Acute, Stroke, Ischemic, Cerebral Infarction","enrollment":458},{"nctId":"NCT06316570","phase":"PHASE3","title":"Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-04-03","conditions":"Ischemic Stroke, Acute","enrollment":1382},{"nctId":"NCT06853535","phase":"PHASE3","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2025-05-23","conditions":"Acute Ischemic Stroke, Clopidogrel Resistance","enrollment":5138},{"nctId":"NCT07238764","phase":"NA","title":"OCT-based DAPT Cessation in HBR Patients","status":"COMPLETED","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2022-06-12","conditions":"High Bleeding Risk Patients, DAPT(Dual Antiplatelet Therapy), Coronary Artery Disease","enrollment":40},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT03551964","phase":"PHASE4","title":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2018-08-01","conditions":"Acute Myocardial Infarction, Cardiogenic Shock","enrollment":605},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT04400981","phase":"NA","title":"Clinical Trial on Remote Ischemic Conditioning in Acute Ischemic Stroke Within 9 Hours of Onset in Patients Ineligible to Recanalization Therapies","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2021-08-01","conditions":"Ischemic Stroke","enrollment":80},{"nctId":"NCT06551727","phase":"NA","title":"Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2024-08-15","conditions":"Stroke, Ischemic","enrollment":70},{"nctId":"NCT05335629","phase":"NA","title":"Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-06-01","conditions":"Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular","enrollment":54},{"nctId":"NCT06102720","phase":"PHASE4","title":"Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization","status":"UNKNOWN","sponsor":"Mikhail Zykov","startDate":"2023-01-12","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT05936606","phase":"NA","title":"Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-08-16","conditions":"Coronary Artery Disease","enrollment":3434},{"nctId":"NCT03635749","phase":"PHASE3","title":"Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2018-09-17","conditions":"Acute Stroke, Transient Ischemic Attack","enrollment":6100},{"nctId":"NCT03764241","phase":"PHASE3","title":"Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":280},{"nctId":"NCT05746416","phase":"","title":"Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)","status":"COMPLETED","sponsor":"Hanyang University Seoul Hospital","startDate":"2019-01-02","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":977},{"nctId":"NCT03815175","phase":"NA","title":"XIENCE 28 USA Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2019-02-25","conditions":"Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke","enrollment":1605},{"nctId":"NCT03218787","phase":"NA","title":"XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2017-07-19","conditions":"Coronary Artery Lesions","enrollment":2047},{"nctId":"NCT05000060","phase":"PHASE3","title":"Restart TICrH AP Pilot Trial","status":"UNKNOWN","sponsor":"University of Texas at Austin","startDate":"2022-10-01","conditions":"Traumatic Intracranial Hemorrhage","enrollment":100},{"nctId":"NCT00963781","phase":"PHASE4","title":"Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)","status":"COMPLETED","sponsor":"Scripps Health","startDate":"2009-08","conditions":"Coronary Artery Disease, Coronary Thrombosis","enrollment":219},{"nctId":"NCT03732066","phase":"NA","title":"Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2019-01-14","conditions":"Coronary Disease","enrollment":760},{"nctId":"NCT03786757","phase":"PHASE3","title":"Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-04-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":200},{"nctId":"NCT00335452","phase":"PHASE3","title":"Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Acute Coronary Disease, Angina Unstable","enrollment":25086}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ticagrelor and Aspirin"],"phase":"phase_3","status":"active","brandName":"Early Dual Antiplatelet Therapy","genericName":"Early Dual Antiplatelet Therapy","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events. Used for Acute ischemic stroke (early intervention), Acute coronary syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}